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“It’s always nice with a hit“ 
Marcus Ingman (1959-)  
 
“Music was my first love” 
John Miles (1949-) 




Aciclovir (ACV) and its prodrug valacyclovir (VACV) are used to treat infections 
caused by herpes simplex virus (HSV) and varicella zoster virus (VZV), and as 
prophylaxis against cytomegalovirus (CMV) infections in immunocompromised 
patients. Treatment with ACV has decreased the mortality in herpes simplex 
encephalitis (HSE) from about 70 % to less than 30 %, and has also reduced the 
morbidity. ACV is excreted mainly by the kidneys, while a minor proportion is 
metabolized to 9-carboxymethoxymethylguanine (CMMG) and 8-hydroxy-ACV. It 
has been found that CMMG concentrations increase if renal function is decreasing. 
ACV is considered to have low toxicity and benign side effects. However, increasing 
serum creatinine and acute renal failure have been reported, and in rare cases 
aciclovir-induced neuropsychiatric symptoms (AINS) have developed. The 
mechanism behind AINS is unknown.  
 
The aim of this thesis was to investigate if there is a correlation between increased 
serum and cerebrospinal fluid (CSF) concentrations of CMMG, and the development 
of AINS. In paper I we studied the ACV and CMMG serum concentrations in 44 
asymptomatic patients and 49 patients with AINS. The CMMG concentration was 
significantly higher in AINS patients than in the asymptomatic group (p<0.001). A 
ROC analysis showed that a cut-off value of 11 µmol/L had the highest sensitivity 
and specificity to predict AINS compared to other predictors, such as ACV exposure, 
ACV concentrations and renal function tests.  
 
The hypothesis that CMMG is directly involved in AINS implies that it is present in 
the CNS. In paper II we did find measurable concentrations of CMMG in CSF, but 
only in subjects with AINS. Asymptomatic control subjects had CSF CMMG levels 
below the limit of detection.  
 
Paper III is a description of two cases developing Cotard’s syndrome- a delusion of 
being dead- as a result of ACV treatment. Both patients had high serum 
concentrations of ACV and CMMG.  
 
In paper IV the signs and symptoms pattern of AINS were analyzed in a larger group 
of patients. We retrieved data from published case reports, ADR cases reported to the 
Swedish Medical Products Agency and from our own Therapeutic Drug Monitoring 
database, in all 275 cases. We also compared AINS with signs and symptoms from 
herpes encephalitis (HSE). The study confirmed that altered level of consciousness, 
confusion, and hallucinations were the most frequent clinical characteristics of AINS, 
while HSE patients presented with high fever, altered level of consciousness, focal 
neurological signs, and headache. 
 
Paper V is a single-dose, open-label pharmacokinetic crossover study with one 
intravenous part and one oral part. We found that CMMG levels in hemodialysis 
patients were more than 10 times higher than in healthy volunteers. Subjects with 
normal and moderately impaired renal function had CMMG levels close to, or below, 
measurable concentrations. 
 
The results of this thesis support the hypothesis that CMMG is a useful predictor of 
AINS and that it may be mechanistically involved. Symptoms of AINS cannot always 
be reliably discriminated from symptoms of HSE, and vice versa. Determination of 
serum and CSF CMMG concentrations may be a useful tool to diagnose AINS and 
when distinguishing between AINS and HSE. Dose regimens aimed to minimize 
CMMG exposure can be developed based on the PK results. 
  
LIST OF PUBLICATIONS 
This thesis is based on the following publications and manuscripts, referred to in the 
text by their Roman numerals: 
 
I. Helldén A, Odar-Cederlöf I, Diener P, Barkholt L, Medin C, Svensson J-O, 
Säwe J, Ståhle L. High serum concentrations of the acyclovir main metabolite 
9-carboxymethoxymethylguanine in renal failure patients with acyclovir-
related neuropsychiatric side effects.  
Nephrol Dial Transplant. 2003 Jun;18(6):1135-41 
 
II. Helldén A, Lycke J, Vander T, Svensson JO, Odar-Cederlöf I, Ståhle L.  
The aciclovir metabolite CMMG is detectable in the CSF of subjects with 
neuropsychiatric symptoms during aciclovir and valaciclovir treatment.  
J Antimicrob Chemother. 2006 May;57(5):945-9. Epub 2006 Mar 15. 
 
III. Helldén A, Odar-Cederlöf I, Larsson KA, Fehrman-Ekholm I, Lindén, T.  
Death delusion.  
BMJ. 2007 Dec 22;335(7633):1305 
 
IV. Helldén A. Lindén T, Odar-Cederlöf I, Bergman U, Ståhle L.  
Clinical characteristics of aciclovir-induced neuropsychiatric symptoms in 275 
patients. (In manuscript) 
 
V. Helldén A, Odar-Cederlöf I, Pohanka A, Ståhle L.  
Single-dose pharmacokinetics of acyclovir and its principal metabolite 9-
carboxymethoxymethylguainine (CMMG) in subjects with normal and 






Mahad D, Jarvis J, Chinnery PF, Mitra D, Gholkar A, Helldén A. Aciclovir induced 
posterior leucoencephalopathy. J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1308-9. 
 
Helldén A, Bergman U, Dwyer, R, Medin C, Molanaei H, Ståhle L. Thylén L, Odar-
Cederlöf I. Risk för CNS-biverkningar av aciclovir och valaciclovir- se upp med 
njurfunktionen! [Risk of CNS adverse effects of aciclovir and valaciclovir. Watch the renal 
function in treatment of herpes simplex and herpes zoster]  Läkartidningen, 
förhandspublicerad på nätet 2007-05-10, i tryckt version 2007;24-25,1916-20.  
 
van Berlo-van de Laar IRF. Goet ER, Helldén A, Sluiter HE. [Adverse effect of valaciclovir 
in disturbed kidney function) Neurotoxiciteit door valaciclovir gebruik bij patiënten met 
nierfunctiestoornissen: wanneer meten van aciclovir en 9-carboxymethoxymethylguanine 





1 Introduction.................................................................................................... 1 
1.1 General introduction............................................................................. 1 
1.2 The index case ...................................................................................... 2 
1.3 Herpes simplex ..................................................................................... 5 
1.3.1 Latency and reactivation .......................................................... 5 
1.3.2 Neonatal HSV2 ........................................................................ 5 
1.3.3 Herpes encephalitis................................................................... 5 
1.3.4 Clinical features of HSE........................................................... 5 
1.3.5 Management of HSE ................................................................ 6 
1.4 Varicella and herpes zoster................................................................... 7 
1.4.1 Age-related reactivation ........................................................... 7 
1.4.2 Herpes zoster encephalitis (HZE)............................................. 7 
1.4.3 Treatment of Herpes Zoster (shingles) ..................................... 7 
1.5 Aciclovir ............................................................................................... 8 
1.5.1 Aciclovir mode of action.......................................................... 8 
1.5.2 ACV pharmacokinetics ............................................................ 8 
1.5.3 ACV side effects ...................................................................... 9 
1.5.4 Possible toxicity of CMMG ..................................................... 9 
1.5.5 HSV and VZV sensitivity (IC50) to ACV............................... 10 
1.6 Therapeutic drug monitoring (TDM) ................................................. 10 
1.7 Drug analysis ...................................................................................... 10 
1.7.1 Presently used HPLC assay and determination of CMMG.... 10 
1.8 Aciclovir-induced neuropsychiatric symptoms (AINS)..................... 11 
1.8.1 Background ............................................................................ 11 
1.8.2 A definition of AINS.............................................................. 11 
1.8.3 Relation between increased ACV concentrations and AINS . 11 
2 AIMS............................................................................................................ 12 
3 Methods and results ..................................................................................... 13 
3.1 Patients ............................................................................................... 13 
3.2 Data collection.................................................................................... 14 
3.3 Renal function tests ............................................................................ 14 
3.4 TDM assays........................................................................................ 14 
3.5 Statistical methods.............................................................................. 14 
3.6 Paper I................................................................................................. 15 
3.6.1 Study design ........................................................................... 15 
3.6.2 Results .................................................................................... 15 
3.7 Paper II ............................................................................................... 16 
3.7.1 Study design ........................................................................... 16 
3.7.2 Results .................................................................................... 16 
3.8 Paper III .............................................................................................. 17 
3.8.1 Study design ........................................................................... 17 
3.8.2 Results .................................................................................... 17 
3.9 Paper IV.............................................................................................. 18 
3.9.1 Study design ........................................................................... 18 
3.9.2 Preliminary results.................................................................. 18 
  
3.10 Paper V..................................................................................................... 20 
3.10.1 Study design..................................................................................... 20 
3.10.2 Preliminary results ........................................................................... 20 
3.10.3 ACV and CMMG PK and renal function ........................................ 21 
4 Discussion.............................................................................................................. 22 
4.1 Paper I .......................................................................................................... 22 
4.2 Paper II......................................................................................................... 24 
4.3 Paper III ....................................................................................................... 26 
4.3.1 The syndrome .................................................................................. 26 
4.3.2 Might cerebral lesions be the cause? ............................................... 26 
4.4 Paper IV ....................................................................................................... 26 
4.4.1 Other symptoms............................................................................... 27 
4.4.2 Investigations ................................................................................... 27 
4.4.3 AINS and delirium........................................................................... 27 
4.4.4 Conclusion paper IV ........................................................................ 27 
4.5 Paper V ........................................................................................................ 27 
4.6 Other aspects of Ains ................................................................................... 29 
4.6.1 How to explain the lack of relation between high ACV 
concentrations and AINS? ........................................................................... 29 
4.6.2 Treatment of AINS .......................................................................... 29 
4.6.3 Are there any other possible causes to the development of AINS?. 30 
5 Future perspectives and general conclusions......................................................... 31 
5.1 Future perspectives ...................................................................................... 31 
5.2 Conclusions.................................................................................................. 32 
6 Acknowledgement................................................................................................. 33 
7 References ............................................................................................................. 35 
 
  




ACV-TP Aciclovir triphosphate 
ADH Alcohol Dehydrogenase 
ADR Adverse Drug Reaction 
ALDH Aldehyde Dehydrogenase 
AUC Area Under the Curve 
CKD Chronic Kidney Disease 
CL Clearance 
Cmax Maximum concentration 
CNS Central Nervous System 
CrCL Creatinine Clearance 
CSF Cerebrospinal Fluid 
CMMG 9-Carboxymethoxymethylguanine 
ELISA Enzyme-linked immunosorbent assay 
ESRD End-Stage Renal Disease 
IC50 Mean 50% inhibitory concentration 
GCV Ganciclovir 
GFR Glomerular Filtration Rate 
HD Hemodialysis 
HPLC High Pressure Liquid Chromatography 
HSV Herpes Simplex Virus 
i.v. Intravenous 
LC-MS Liquid Chromatograph-Mass Spectrometry 
LOQ Limit of Quantification 
MDRD Modification of Diet in Renal Disease 
MRI Magnetic Resonance Imaging 
PCR Polymerase Chain Reaction 
PD Peritoneal Dialysis 
PDR Physicians Desk Reference (FASS in Sweden) 
PK Pharmacokinetics 
qid “quater in die” (four times a day) 
RIA Radioimmunoassay 
SWEDIS Swedish Drug Information System 
t½ Half-life 
tds “ter die sumendum” (three times a day) 
TDM Therapeutic Drug Monitoring 
VACV Valaciclovir 
VZV Varicella Zoster Virus 
 

   1 
1 INTRODUCTION 
 
1.1 GENERAL INTRODUCTION 
The antiviral drug aciclovir1 (ACV) is used to treat infections caused by 
alphaherpes viruses, i.e. herpes simplex virus (HSV) and varicella (herpes) zoster 
(VZV), and the betavirus cytomegalovirus (CMV). It is the drug of choice for 
treatment of neonatal herpes simplex virus (HSV) infections, herpes simplex 
encephalitis (HSE), and HSV and VZV infections in immunocompromised 
patients. Valaciclovir (VACV), the L-valyl ester of ACV is also used as 
prophylaxis against CMV infections in solid organ recipients and bone marrow 
transplanted patients. 
 
ACV is considered to have low toxicity compared to other antiviral drugs with 
effect against these viruses, such as ganciclovir (GCV), foscarnet and cidofovir 
(CDV) [1]. Common side effects include nausea, vomiting, diarrhoea, and 
headache [2]. Other side effects such as increasing creatinine and acute renal 
failure have been reported in dehydrated patients or in cases where ACV has been 
given too fast intravenously (i.v.) [3,4].  
 
In spite of its low toxicity, aciclovir-induced adverse drug reactions from the 
central nervous system (CNS) have been reported. These symptoms, in general 
designated as neurotoxic or neuropsychiatric, have caused suffering for patients 
and costs for the health system. The mechanism behind CNS-effects is unknown. 
High ACV concentrations have been reported [5], while others have shown normal 
levels [6]. Aciclovir-induced neuropsychiatric symptoms (AINS) have in several 
cases been difficult to distinguish from CNS symptoms caused by the infection it is 
treating (confounding by indication). On suspicion of herpes or zoster encephalitis 
the doses have been increased and changed from oral to intravenous administered 
drug, which in turn has worsened the condition [7,8]. 
 
In this thesis I put forward a hypothesis that increased concentrations of the ACV 
main metabolite 9-carboxymethoxymethylguanine (CMMG) is a marker for and 
possibly also a cause of AINS. I will also suggest that Therapeutic Drug 
Monitoring (TDM) of CMMG may be a simple and fast diagnostic tool to 
distinguish between AINS and symptoms of CNS infections.  
 
The thesis will present various aspects of the discipline Clinical Pharmacology. My 
work starts with a case report of an adverse drug reaction and demonstrates the 
usefulness of a TDM database, continues with clinical pharmacology and 
epidemiology studies describing the pattern of AINS and ends with a 
pharmacokinetic (PK) study.  
 
                                                
1 ACV is sometimes spelled acyclovir and sometimes aciclovir. The reason for this discrepancy is 
unclear to me, but acyclovir is referring to “Acyclovir, an acyclic purine nucleoside analog [32] and 





1.2 THE INDEX CASE 
 
In April 1994, one of my diabetic patients on peritoneal dialysis (PD) training 
presented with blisters on his chest. Herpes simplex (HS) was suspected but, as the 
patient had been a predialysis patient for some time and was likely to have an 
impaired immune system, shingles, or varicella zoster, could not be ruled out. 
Shingles was suspected despite the fact that the blisters appeared on both sides of 
the chest, while they usually appear unilateral. Aciclovir treatment was planned to 
be initiated with a dose adapted for the renal function (oral ACV 800 mg x 2) 
according to the dose recommendation in the Swedish PDR (Physicians Desk 
Reference).  
 
Earlier experiences among colleagues at the Department of Nephrology revealed 
that CNS ADRs had occurred in some patients with end-stage renal disease 
(ESRD), but the relation to aciclovir dose or concentration was not clear. I therefore 
decided to contact the Zovirax® (ACV) product specialist at GlaxoWellcome to get 
advice regarding dose recommendations for PD patients. In a letter that I received 
the day after the first telephone discussion, I was advised to follow the 
recommendations in the PDR to avoid treatment failure. I was also told that the 
Department of Clinical Pharmacology at Huddinge University Hospital, Stockholm, 
had a method for analysing ACV concentrations. I decided to give the 
recommended dose, but also to measure the ACV concentrations during the 5 day 
treatment period, both in serum and in PD effluent. The patient agreed on visiting 
the department every morning during that period, bringing his PD bags from the 
previous evening and night. A swab was used for diagnostic tests of the blisters. 
Concomitant treatment was ciprofloxacin and vancomycin, instituted some weeks 
before the event due to a skin infection. He was also treated with other drugs 
commonly seen in dialysis patients, and there had been no changes in the treatment 
regiment.  
 
The patient took the first 800 mg ACV dose in the afternoon. The next day he came 
to the clinic at noon collecting blood and leaving PD-effluent. He also administered 
the second 800 mg ACV dose before leaving the department. The patient called me 
that same evening. He told me that about 3 hours after the second ACV dose he had 
begun to feel strange and oddly depersonalized. He wondered if the ACV treatment 
might be causing the symptoms. I decided to withdraw ciprofloxacin, which is 
known to cause CNS adverse reactions, but to continue with ACV.  
 
The patient did not turn up to collect blood and leave his PD bags the next morning. 
I called him at noon, and a tired patient answered saying: “I´ve had the worst night 
of my life! I’ve been awake all night, afraid to fall asleep, because whenever I 
closed my eyes I saw snakes and flies and multiple TV-sets. I’m aching all over and 
my hands are shaking! Even though I’ve never tried illegal drugs, I’m sure you can 
compare this horrifying experience with a bad trip on LSD!” 
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The patient finally came to the department, but not until 4 o’clock in the afternoon. 
He had had no further hallucinations, but his hands were still shaking and he was 
still very tired. He said that his wife had taken the ACV pills and flushed them 
down the toilet. I made a physical examination of the patient; it was negative 
except for the tremor and a slight increase in blood pressure. Blood and PD 
effluent samples from the patient were collected. I explained that he had probably 
experienced a severe ADR and that I wanted to investigate the cause.  
 
He continued having tremor and muscle pain for another five or six days, but did 
not experience any other symptoms. ACV concentrations in serum were not 
remarkably high and seemed not to provide an explanation to the course of events 
(Figure 1).  
 
 
Figure 1. ACV serum and PD-effluent concentrations collected from the index patient. Note that 
the serum ACV peak concentration was increased, but not remarkably high. When dosing with 
ACV 800 mg x 5 ACV concentrations ranging from min-max 3.5-6.9 µmol/L has been reported in 
patients with normal renal function. Each arrow represents an oral ACV 800 mg dose. IC50 for 
effect against HSV1 and HSV2, VZV, and CMV have been shown to be 0.3 µmol/L, 3.0 µmol/L, 
and > 30 µmol/L, respectively [9].  
 
Ciprofloxacin and vancomycin drug levels were also measured, but were within 
therapeutic range. The result from the blood test was normal, except for a slight 
increase in CRP. ACV seemed to be the sole culprit, but as ACV levels were 
increased, though not abnormally high, I excluded it from the list of suspected 
drugs. The key to the answer was yet to be found.  
 
Approximately one year later, after having done literature research, I decided to 
once more take contact with the Department of Clinical Pharmacology. Supported 
by my senior consultant, Dr Anders Tranæus, I asked if they could find any ACV 
metabolites in the serum collected from my patient. Their answer was that they did 
find increased concentrations of the ACV main metabolite 9-
carboxymethoxymethylguanine (CMMG) (Figure 2). The CMMG increase 
correlated in time with the patients neuropsychiatric symptoms. In addition, I was 
told that they had seen increased concentrations of CMMG also in other patients 
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reported to have suspected CNS side effects, but that the finding had not yet been 
explored.  
 
Was my patient the only case or could I find other AINS patients with increased 
CMMG concentrations? To find an answer to this question I investigated an ACV-
treated group of ESRD patients with and without suspected AINS. ACV, but not 
CMMG, serum concentrations had earlier been measured in these patients, making 
a blinded comparison possible. The result was promising! AINS patients had high 
CMMG concentrations while asymptomatic patients had low concentrations. The 
moment I received these results marked the beginning of my career as a scientist!   
 
 
Figure 2. This is figure 1 with addition of CMMG concentrations. When serum and PD-effluent 
concentrations were analyzed, they initially showed a steep increase in ACV and CMMG levels, 
corresponding to the initial neuropsychiatric symptoms. Still seven days after the first ACV dose 
CMMG levels remained increased and the patient had persistent muscle pain and tremor. Each 
arrow represents an oral ACV 800 mg dose.  
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1.3 HERPES SIMPLEX  
The word “herpes” derives from ancient Greek and means to “creep” or “crawl”. 
Herpes diseases have been known to man for at least three millennia. Both herpes 
simplex (HSV) and varicella zoster (VZV) viruses are ubiquitous human alphaherpes 
double-stranded DNA-viruses. HSV is divided into two subgroups. HSV1 is usually 
transmitted during early childhood and seropositivity has reached 80-90 % worldwide. 
HSV2 is still the most common cause of sexually transmitted HSV infections. HSV is 
transmitted via mucosal surface or damaged skin, HSV1 usually via the orolabial route 
and HSV2 normally through sexual contact. However, HSV1 can also cause genital 
herpes and HSV2 can also cause herpes labialis [10].  
 
1.3.1 Latency and reactivation 
A primary HSV infection may be asymptomatic, but is clinically recognised by the 
presence of typical herpes vesicles. After entering the body the virus is transported 
via the fast axonal retrograde transport to the soma of neuron, where it can rest for a 
long period of time. Sunbathing, having a cold or being exposed to stress may 
activate the virus, but the mechanism behind reactivation is still unknown. After 
reactivation the virus is transported into the nerve axon and back to the skin or 
genitals, where it causes painful blisters and ulcers. Recurrent HSV infections are 
usually mild, but may be traumatic and embarrassing. HSV can also cause more 
severe diseases such as neonatal HSV2 and herpes encephalitis (HSE) [10].  
 
1.3.2 Neonatal HSV2 
Neonatal HSV2 is a disease with high mortality and morbidity despite aciclovir 
treatment. The virus is transferred to a child during birth. ACV prophylaxis during 
pregnancy has been discussed, but since the drug may cause neutropenia and 
nephrotoxicity ACV prophylaxis has not been supported [10]. In neonates the 
standard dose of ACV is 60 mg/kg/day.  
 
1.3.3 Herpes encephalitis 
Herpes encephalitis (HSE) is a devastating infection in the CNS and the primary cause 
of sporadic fatal encephalitis in the United States [11,12]. Before effective antiviral 
treatment was available approximately 70 % of all infected died and the remaining 25-
30 % suffered from severe sequelae such as memory impairment or seizures. 
Intranuclear inclusion bodies with HSV infection were demonstrated for the first time 
in the brain of a neonate in 1941, and the virus was subsequently isolated from the 
patient’s brain tissue [13]. HSE can occur in all age groups, but has a bimodal 
distribution. Roughly 30 % of all infected are below 20 years of age and 50 % are over 
50 [11,14]. The annual incidence in USA has been estimated to be 2000 cases [15]. In 
Sweden, the annual incidence is 2.2 per million inhabitants, corresponding to 20 cases 
per year [16]. Most infections (90 %) are due to HSV1 [17].    
 
1.3.4 Clinical features of HSE 
Distinguishing between viral infection and AINS is a diagnostic and therapeutic 
challenge. Since ACV should be instituted without delay in every suspected case of 
HSE, knowledge of the clinical features of HSE is important early in the diagnostic 
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procedure, when still waiting for results from herpes PCR and neuroimaging. Several 
retrospective and prospective studies on the clinical features of HSE have been reported 
and some of them are presented in Table 1. The prodromal symptoms may include 
influenza-like illness, high fever, and headache. Later clouding of consciousness and 
confusion may develop [18-21] (Table 1).   
 
Table 1. Clinical features of herpes simplex encephalitis (HSE) 
 
Study Kennedy Sköldenberg Whitley McGrath  
No of patients 46 53 28 42
       
Symptoms Per cent of investigated patients 
Influenza-like symptoms 48 %     
Headache, confusion and alteration of the level of 
consciousness 52 %     
Confusion/Disorientation    67 %
Altered consciousness  100 % 96 % 90 %
 Lethargy  (57 %) (39 %)   
 Semicoma   (30 %) (25 %)   
Deep coma 35 % (13 %) (36 %)   
Fever 100 % 100 % 96 % 98 %
Personality changes 87 % 95 % 24 %
Headache 74 % 82 % 74 %
Meningism 65 %   55 %
Drowsiness 65 %   45 %
Muteness, dysphasia, or aphasia 46 % 36 % 88 % 28 %
Raised intracranial pressure 33 %     
Focal neurological signs 89 %     
Seizures 61 % 62 % 57 % 50 %
- Focal (50 %)  (43 %)   
 -Generalised (9 %)  (14 %)   
- Focal and generalized (2 %)     
Vomiting  38 % 46 %   
Disorientation  57 % 93 %   
Hemiparesis  40 % 43 % 33 %
Lethargy    24 %
Memory loss   18 %   
Photophobia   4 %   
Autonomic-nervous system dysfunction   75 %   
Ataxia     67 %   
 
 
1.3.5 Management of HSE  
HSV encephalitis is a medical emergency. Immediate and accurate diagnosis with the 
use of lumbar puncture, neuroimaging, and PCR is crucial. ACV is the first line 
treatment and should be initiated in every suspected case. Normal dosing is 10 mg/kg 
intravenously every 8 h (30 mg/kg/day) for 14 days, 21 days for immunocompromised 
patients. The dose should be adapted to renal function [15,22,23]. Early treatment is 
crucial to prevent severe sequelae and to decrease mortality.  
 
ACV is nowadays instituted in nearly all cases with suspected encephalitis, even if 
the diagnosis is unclear. There are mainly two drawbacks to this procedure: firstly, it 
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creates a feeling of safety and might prolong the time to actual diagnosis, secondly, it 
may cause nephrotoxicity and AINS [15].  
 
1.4 VARICELLA AND HERPES ZOSTER 
Varicella (chickenpox) is caused by the varicella zoster virus (from latin “variola”= 
little pox and the Greek word “zoster”= girdle) and affects mainly children and 
adolescents. The seroconversion rate is about 95 % in children in United States [24]. 
The virus may be latent in the cranial and dorsal root ganglia of sensory nerves for 
many years, but can reactivate to herpes zoster or shingles (from Latin “cingulum”= 
belt or girdle). Shingles is also called “Zona”, “Gürtelrose”, or “Hells fire”.  
 
1.4.1 Age-related reactivation 
Reactivation may occur in any age group, but the risk increases with age. A study 
showed an annual incidence of 200 cases per 100 000 population at the age of 30, but 
increased to 800-1200/100 000 at the age of 80 [25]. Reactivation occurs in the ganglia, 
the virus travels along the sensory nerve into the skin and causes shingles. Shingles 
affects the dermatom which the ganglia innervate. Shingles are painful and can cause 
postherpetic pain, which can persist for months [26]. As with HSV, the reason why the 
virus reactivates is still not known, but stress, diseases such as HIV or cancer, or 
treatment with immunosuppressants, increases the risk.  
 
1.4.2 Herpes zoster encephalitis (HZE) 
An increasing body of evidence indicates that HZE is more common than earlier 
believed. In a Finnish collaborative study of 3231 patients, VZV was the main agent 
associated with encephalitis, followed by HSV and enteroviruses. Improved diagnostic 
methods, especially PCR, can be a factor explaining the increase [27]. In a later study 
the same group found that 44 % of 174 patients with PCR-proven VZV had no 
cutaneous symptoms at all, 34 % had shingles and 22 % had chickenpox. Of interest for 
this thesis is the finding that HZE clinical symptoms were similar to AINS [28].  
 
1.4.3 Treatment of Herpes Zoster (shingles)  
The recommended doses for treatment of shingles are usually higher than for treatment 
of HSV. The doses for patients with normal renal function are 1000 mg x 3 or 800 mg x 
5. For patients with renal impairment (GFR 10-30 mL/min) the recommended dose is 
VACV 1000 mg x 1 or oral ACV 800 mg x 3. For patients with ESRD the doses are 
VACV 500 mg x 1 or oral ACV 800 mg x 2, but may probably be too high for 







The high mortality and morbidity in HSE prompted studies on antiviral drug 
candidates. Several attempts were made to find a drug that was easy to administer, 
nontoxic, and with a favourable pharmacokinetic profile. Compounds such as 
trifluorothymidine, idoxuridine (5-iodo-2’-deoxyuridine) and ara-C (1-beta-D-
arabinofuranosyl cytosine) were tested, but found to be too toxic (ara-C is now a 
frequently used chemotherapeutical- cytarabine). However, vidarabine (adenine 
arabinoside) was reported to be effective against both HSE and HZE, but could only be 
administered intravenously [18]. An extensive search for a more effective and less 
toxic compound was begun at Burroughs Wellcome in the early 1960s [29]. Aciclovir 
was discovered in 1974 [30] and after intense preclinical testing the drug entered 
clinical development in 1977. The results from phase II studies brought topical, 
intravenous and oral formulations to the market, starting with the topical form in 
1982 [29].  
 
 
1.5.1 Aciclovir mode of action 
When ACV enters a virusinfected cell the viral thymidine kinase phosphorylates ACV 
to ACV-monophosphate, which subsequently is phosphorylated by cellular enzymes to 
the active substance ACV-triphosphate (ACV-TP) [31,32]. ACV inhibits the synthesis 
of viral DNA by eventually incorporating ACV-monophosphate into the viral DNA in 
an irreversible process. ACV also inhibits the viral DNA polymerase. The human 
thymidine kinase has a much lower affinity for ACV than the viral kinase. Uninfected 
cells will thus only form small amounts of ACV-TP. Other drugs, such as famciclovir 
(FCV), brivudin (BVDU) and ganciclovir (GCV), use the same viral mechanism [1]. 
An in vitro-study showed that it takes roughly 6-8 hrs to reach maximum intracellular 
amounts of ACV-TP in HSV-infected Vero cells [33]. Yet another in vitro-study 
showed that ACV-TP had an intracellular half-life of 1-2 hours [34].    
 
1.5.2 ACV pharmacokinetics 
1.5.2.1 General pharmacokinetics 
ACV is a small molecule with a molecular weight of 225 D. The protein binding is 
around 10-20 %. Oral ACV has a low and dose dependant bioavailability (F), ranging 
from 9 % to 23 %. Steady-state peak plasma2 concentrations after 200, 400 and 600 
mg of ACV every 4 hrs were 2.22 ± 0.0, 5.3 ± 1.3 and 5.8 ± 1.3 µmol/L, respectively. 
Total oral body clearance (ACVCL tot) was 1884 ± 464, 1765 ± 652 and 2217 ± 1217 
mL/min/1.73m2, respectively.  Half-life was 3.3 ± 0.4 hrs [35]. The major route of 
elimination is by glomerular filtration and tubular secretion [36]. The development of 
VACV, the L-valyl ester of ACV, improved the oral ACV bioavailability from 9-23 
% to 50-70 %. Early studies found that over 95 % of ACV was excreted unchanged in 
the urine in healthy subjects. A small fraction was excreted as the main metabolite 9-
carboxymethoxymethylguanine (CMMG) and less than 0.2 % was excreted as 8-
hydroxy-9-(2-hydroxyethoxymethyl)guanine (8-OH-ACV) [37]. A later VACV study 
reported that the majority of recovered ACV in urine was acyclovir (84.3 ± 4.7 %), 
                                                
2 ACV concentrations were analyzed in plasma in early studies, while serum was used at our laboratory.  
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CMMG (13.8 ± 4.2 %) and 8-OH-ACV (1.5 ± 1.1 %) [38]. A VACV dose of 1000 
mg every 8 h produced an exposure (AUC) similar to an i.v. ACV dose of 5 mg/kg 
tds [28]. 
 
1.5.2.2 ACV metabolism 
In vitro studies suggested that ACV was metabolised to CMMG by alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), the two main enzymes 
metabolizing ethanol. Aldehyde oxidase was responsible for the formation of 8-OH-
ACV [39]. Aciclovir aldehyde, the proposed intermediate formed by ADH, has been 
synthesized and is readily convertible back to ACV, as well as to CMMG [40]. Early 
studies showed that a greater amount of ACV is excreted as CMMG when renal 
function is declining [35]. Both ADH and ALDH enzymes are polymorphic and may 
thus have different metabolic capacity [41].  
 
1.5.2.3 Intravenous administration 
The pharmacokinetics of i.v. ACV can be described by a 2-compartment model [35, 
42], although a 1-compartment model has also been used [43]. Total ACV clearance 
after i.v. infusion ranged from 117 to 396 mL/min/1.73m2 [44].  
 
1.5.2.4 Impaired renal function 
Total ACV clearance decreases with age, probably due to the physiological decrease of 
renal function in elderly patients. A linear relation between total ACV clearance and 
CrCL has been reported: total ACV clearance = 28.7 + 3.37*CrCL. The terminal 
plasma half-life in ESRD patients ranged from 13-29 hours, (mean ± SD) 19.5 ± 5.9 
hrs. A single hemodialysis reduced the plasma ACV concentrations by 60 % [35].  
 
1.5.2.5 ACV in CSF 
The concentration of ACV in CSF has been reported to be about 50 % of the ACV 
serum concentrations, irrespective of route of administration [36].  
 
1.5.3 ACV side effects 
The neuropsychiatric side effects reported are discussed in section 1.8. Other ACV-
induced side-effects, such as bone-marrow toxicity [45] and nephrotoxicity, have also 
been reported [46-50]. The mechanism behind the development of acute renal failure 
(ARF) is still under debate. It has been suggested that rapid infusion of ACV may 
cause ARF due to precipitation of ACV crystals in the tubular cells [4, 51-56]. 
Gunness et al suggested in an in vitro study that acyclovir may induce direct insult to 
renal proximal tubular cells [57].  
 
1.5.4 Possible toxicity of CMMG 
A thorough search on CMMG toxicity in relevant databases, such as PubMed, Embase 
and similar sources, gave no information on toxicity. This was confirmed by 
GlaxoSmithKline, stating that pre-clinical studies conducted during the development 
of ACV did not focus on CMMG. Accordingly, the company does not have pre-
clinical data relating to CMMG and the occurrence of neurological events (Steve 
Weller, GlaxoSmithKline, personal communication, 2010) 
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1.5.5 HSV and VZV sensitivity (IC50) to ACV 
When dosing ACV it is important to know the antiviral activity of the drug, especially 
as different types of herpesviruses will show different susceptibility. The ACV antiviral 
activity has been measured by in vitro systems showing that HSV1 and HSV2 had low 
(IC50) values, approximately < 0.3-0.3 µM, VZV about 3.0 µM and CMV >30 µM [9]. 
These in vitro values depend on the particular in vitro system used. It therefore cannot 
be taken as a predictive measurement of clinical efficacy but can give a guide to 
relative efficacy. 
 
1.6 THERAPEUTIC DRUG MONITORING (TDM) 
One definition of TDM is “The regular measurement of serum levels of drugs requiring 
close 'titration' of doses in order to ensure that there are sufficient levels in the blood to 
be therapeutically effective, while avoiding potentially toxic excess; drug concentration 
in vivo is a function of multiple factors” [58]. Some of these factors are conditions that 
may affect drug absorption, metabolism or renal excretion and drug-drug interactions 
(DDIs), like the previously reported interaction between fluconazole and phenytoin 
[59]. TDM is important for measuring concentrations in drugs with a narrow 
therapeutic range (e.g. phenytoin), to avoid toxicity or subtherapeutic concentrations, 
and to measure compliance. 
 
1.7 DRUG ANALYSIS 
The high-pressure liquid chromatography (HPLC) method, published in 1977 in the 
classic paper by Gertrude Elion et al, was the first method to measure ACV and 
metabolites in blood, CSF and urine [31]. Several other methods have been published 
[60-63]. To our knowledge there is only one documented instance in which CMMG has 
been found in human plasma [64]. 
  
1.7.1 Presently used HPLC assay and determination of CMMG  
In 1993-94 a prospective study was carried out of high-dose ACV prophylaxis against 
CMV infections in liver recipients [65]. As a part of this project an assay to analyze 
ACV was developed in order to provide rapid analysis results. The method, a reversed-
phase solid-phase extraction and HPLC, had the advantage that it could separate 
CMMG from ACV (Figure 3) [66]. This separation was earlier only possible using the 
radioimmunoassay method. The assay became available for clinical use in 1991.   
 
 Figure 3. The chromatography shows separation of CMMG from ACV [66] [Jan-Olof Svensson, Lisbeth 
Barkholt, Juliette Säwe. Copyright (1997), with permission]  
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1.8 ACICLOVIR-INDUCED NEUROPSYCHIATRIC SYMPTOMS (AINS) 
 
1.8.1 Background 
Case reports on CNS adverse reactions appeared in the medical journals soon after 
ACV had been established on the market in the beginning of the 1980th century [6,45, 
48,49,67-72].  
 
Five years after the introduction of ACV, and when it had been used in over 10 
million courses of treatment, the results from a comprehensive epidemiology 
monitoring program was published. The program reported a” remarkably small 
number of reports of serious experiences and, of these, the very few in which 
acyclovir was believed by the reporter to be a cause” [2]. Symptoms from the nervous 
system were the most or the second most common side-effects reported. As an 
example an inpatient monitoring study performed in 10 hospitals found that 22 % of 
739 ACV-treated patients developed neuropsychiatric symptoms compared to 9 % of 
190 controls (p< 0.001) [2].   
 
Despite the increasing knowledge of AINS, case reports continue to be published [73-
80]. Rashiq et al defined the clinical characteristics of aciclovir neurotoxicity in a 
paper published in 1993, including a case series of 35 patients. The authors concluded 
that AINS is a self-limiting, dose dependent phenomenon, predominantly affecting 
elderly patients and patients with renal failure. They also found that it is distinguished 
from viral encephalitis by absence of fever or headache, lack of focal neurological 
findings and normal cerebrospinal fluid [81].  
 
Similar instances of AINS were reported when VACV was introduced on the market in 
1995 [54,82-90]. In a retrospective case series Das et al described 25 cases of AINS in 
167 renal transplant recipients (15%) due to VACV treatment. Delayed graft function3 
was found to be the main risk factor (Odds ratio 12.1; 95 % CI= 3.4-43.3; p< 0.001) 
[91]. An ADR bulletin from the Australian Government Therapeutic Goods 
Administration reported 69 events of VACV adverse reactions. AINS such as dizziness, 
hallucinations, confusion, and delirium were reported [92]. 
 
1.8.2 A definition of AINS 
Several of the CNS adverse reactions described or referred to in this thesis are 
described as “neurotoxic”. We have chosen to call the aciclovir-induced ADRs 
“neuropsychiatric” because patients suffering from AINS exhibit both neurological and 
psychiatric symptoms.  
   
1.8.3 Relation between increased ACV concentrations and AINS  
The occurrence of transient ACV-induced adverse reactions, such as vomiting and 
increasing creatinine in high-dosed subjects in a herpes zoster study suggested that 
there was a dose correlation [93]. Others have reported a correlation between high 
ACV serum concentrations and AINS [5,7,45,48,75,76,83,94-106]. However, low or 
normal ACV concentrations have also been reported [6,54,74,78,107-114]. 
                                                
3 When a transplanted kidney does not function immediately post-transplant and is "sluggish." The 




The primary aim of this PhD work was to investigate if there is a relation between 
ACV, the ACV main metabolite 9-carboxymethoxymethylguanine (CMMG), and the 
development of AINS.  
 
We also wanted to evaluate if determination of ACV and CMMG in serum could serve 
as a diagnostic tool for AINS, and to study ACV and CMMG pharmacokinetics. The 
specific aims in each article were to: 
 
Paper I: investigate the relationship between appearance of AINS and serum 
concentrations of ACV and CMMG, and to compare the sensitivity and specificity of 
CMMG and ACV as predictors of AINS. 
 
Paper II: investigate if CMMG is present in cerebrospinal fluid, and if so, to compare 
the concentrations of CMMG and ACV between subjects with AINS and those without 
symptoms.  
 
Paper III and IV: describe common clinical features of AINS, sometimes with unusual 
but possibly unique symptomathology, and if possible, differentiate between AINS and 
herpes encephalitis symptoms. 
 
Paper V: describe ACV and CMMG pharmacokinetics in subjects with varying degrees 
of renal function.  
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3 METHODS AND RESULTS 
 
3.1 PATIENTS 
Patient data in study I was retrieved from an ACV TDM database at the Department of 
Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden, 
containing 275 ACV/CMMG samples from 130 patients. The majority of the samples 
were collected at the Departments of Infectious diseases, Hematology, and Nephrology 
in Sweden. 
 
In study II, ACV and CMMG CSF concentrations from AINS cases in the ACV TDM 
database were compared with subjects included in a VACV survey, studying the 
possible involvement of herpesviruses in the pathogenesis of multiple sclerosis (MS) 
[115].  
 
In paper III we described two patients with AINS presenting with Cotard’s syndrome- a 
delusion of being dead. One patient was identified during a regular HD session, and 
data concerning the other patient was extracted from the TDM database and the patient 
chart.  
 
Study IV included data from three different sources: 
 
1. ACV or VACV- treated patients with AINS reported to SWEDIS, an ADR 
database at the Swedish Medical Products Agency, including 110 000 causality 
assessed ADRs in Sweden [116]  
2. Data from our TDM database  
3. Published AINS cases from 1981 - 2007 
 
Swedish cases, suspected to be identical due to similarities in age, sex, symptoms, and 
ACV and CMMG concentrations, were included only in the TDM data base. Similarly, 
our previously published cases [117-119] were not included in published AINS cases.  
 
In study V healthy subjects were recruited from a database at the Clinical 
Pharmacology Trial Unit (CPTU) at the Department of Clinical Pharmacology, 
Karolinska University Hospital, Huddinge, Stockholm, Sweden. Subjects with impaired 
renal function or ESRD were recruited from the Department of Nephrology at the 
Karolinska University Hospital.  
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3.2 DATA COLLECTION 
Drug concentrations from study I, II and III were collected from our ACV and CMMG 
TDM database at the Department of Clinical Pharmacology. The database today 
includes more than 1500 ACV and CMMG serum, urine and CSF samples collected 
from more than 500 patients.  
 
3.3 RENAL FUNCTION TESTS 
In paper I the renal function (GFR) was calculated by the MDRD formula. The formula 
was developed by the Modification of Diet in Renal Disease Study Group including 
data on 1600 patients with impaired renal function [120]. The only parameters needed 
for the calculations are S-creatinine, age and correction factors for gender and ethnicity 
(being or not being Afro American). The unit is expressed as mL/min/1.73 m2. The 
MDRD formula was used because weight was lacking in several patients in study I. A 
more appropriate formula, such as Cockcroft Gaults formula, could thus not be used 
without a large drop-out. Note that in paper I the dimension for MDRD is erroneously 
given as mL/min. However, MDRD GFR was used for the GFR calculations in all 
patient groups. Children’s GFR was calculated by Schwartz estimate [121]. The 
Cockcroft Gault formula, without correction for body surface area, was used in paper II 
and V. 
 
3.4 TDM ASSAYS 
TDM serum and CSF samples collected from patients in paper I-III were analyzed by 
the HPLC method developed at our department, as presented in paragraph 1.7.1 [66]. 
In paper V we described a modified assay with increased sensitivity and specificity 
using liquid chromatography- mass spectrometry (LC-MS). The disadvantage with 
the previous HPLC method was that it could not separate CMMG from the antiviral 
drug GCV, which in some situations was used together with ACV. The problem is 
solved by using the LC-MS method.  
 
3.5 STATISTICAL METHODS 
Data on the concentration of ACV and CMMG were analyzed by Student’s t-test. 
Doses were compared by Mann-Whitney U-test. Descriptive statistics were generally 
given as means ± standard deviation (SD), but also as means with 95 % confidence 
intervals. The frequency data were analyzed using χ2 test. Most of the data were 
organized using Microsoft® Excel spreadsheet software (Microsoft Corporation, USA), 
and statistical calculations were mainly performed using Statistica software (Statsoft 
Inc, Tulsa, OK, USA). Conventional receiver-operating characteristics (ROC)4 was 
used in study I [122]. All studies except study V were retrospective.  
  
 
                                                
4  A statistical test that can be used to compare the diagnostic performance of two or more laboratory or 
diagnostic tests. The area under an ROC curve is used as an index of diagnostic performance. 
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3.6 PAPER I 
 
3.6.1 Study design 
Study I was a retrospective study, aiming to test the primary hypothesis of a correlation 
between increased concentrations of CMMG and the development of AINS. The study 
was also aiming to compare the sensitivity and specificity of CMMG, ACV, and other 
parameters such as renal function, as predictors of AINS. Cases and controls were 
retrieved from the TDM database at the Department of Clinical Pharmacology. 




A total of 93 patients were included in the study. Forty-nine patients had suspected 
AINS and 44 were asymptomatic or had other reasons for CNS symptoms. We found a 
statistically significant difference in CMMG serum concentrations between the 
symptomatic and asymptomatic patients (P<0.001), supporting the initial hypothesis. 
Similarly, ACV concentrations also differed significantly between the two groups 
(P<0.01) (Figure 4). The ROC curve for CMMG demonstrated that neuropsychiatric 
symptoms could be predicted with a sensitivity of 91 % and a specificity of 93 % with 
the use of a cut-off value of 11 µmol/L of CMMG. For ACV the sensitivity was 49 % 
and the specificity 93 % using a cut-off value of 15 µmol/L. Seven of the 49 AINS  

















Figure 4 shows the ACV and CMMG serum concentrations in AINS and asymptomatic patients. To 
convert ACV µmol/L to µg/ml, divide by 4.44 and from CMMG µmol/L to µg/mL, divide by 4.18.  
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3.7 PAPER II 
 
3.7.1 Study design 
To be able to treat herpes encephalitis the penetration of ACV into the brain is 
crucial. Early studies reported that about 50 % of the ACV plasma concentrations were 
distributed to CSF [36]. However, these measurements did not include CMMG. The 
presence of the suspected substance in the brain is likewise a prerequisite for the 
development of drug-induced neuropsychiatric symptoms. A study of ACV and 
CMMG levels in CSF in AINS and asymptomatic subjects was therefore conducted. A 
total of 21 subjects were included in the study, of whom nine had AINS. All AINS 
patients, except one, had acute or chronic renal failure [123]. Ten of the asymptomatic 
subjects participated in a pharmacokinetic study on the effects of VACV in multiple 
sclerosis (MS) [115]. The remaining two subjects had relapsing herpes encephalitis.  
 
3.7.2 Results 
CMMG could be detected in CSF only in subjects with AINS, median 1.0 µmol/L 
(range 0.6 – 7 µmol/L). In asymptomatic subjects the concentration of CMMG was 
below the limit of quantification (LOQ) (<0.5 µmol/L)(P < 0.001) (Figure 5). The mean 
ACV and CMMG serum concentrations in the AINS group were 4.6 and 55.4 times 
higher, respectively, compared to asymptomatic patients. The ACV CSF/ACV serum 
ratios in asymptomatic and AINS patients were 0.38 ± 0.34 and 0.88 ± 0.77, 
respectively (p=0.061). The corresponding ratios for CMMG were calculated by 
setting the CMMG CSF concentrations in the asymptomatic patients to the LOQ 
value and were 0.69 ± 0.21 and 0.065 ± 0.037, respectively (p< 0.001). Both ACV 
and CMMG showed a linear relation between serum and CSF concentrations.   
 
Figure 5. CSF concentrations of 9-carboxymethoxymethylguanine (CMMG) and aciclovir (ACV) from 
twelve subjects without and nine subjects with neuropsychiatric symptoms. CMMG was detectable in the 
CSF from symptomatic patients. The twelve subjects without neuropsychiatric symptoms had CMMG 
CSF concentration below the limit of quantification (LOQ) =0.5 µmol/L. CMMG= 9-carboxy-
methoxymethylguanine. 
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3.8 PAPER III 
3.8.1 Study design 
Paper III describes two cases of Cotard’s syndrome- a rare delusion of being dead 
[124]. A female patient was on HD due to a failing kidney transplant and a male patient 
developed acute renal failure after the initiation of VACV treatment. Data concerning 
the two cases were collected both from the patient charts and in collaboration with the 
responsible clinicians. ACV and CMMG concentrations came from the TDM database.  
 
3.8.2 Results 
Within a few days after initiating VACV treatment both patients presented with 
confusion and/or depersonalization, symptoms which soon developed into Cotard’s 
syndrome- the belief of being dead. In the female patient the syndrome subsided during 
a dialysis session. The male patient, who did not receive HD, had CNS symptoms 
during three days, especially at night (Figure 6). ACV and CMMG concentrations in 
serum and CSF were high in both patients. Both patients recovered without sequelae.    
 
 
Figure 6. Acyclovir (ACV) (straight line), 9-carboxymethoxymethylguanine (CMMG) (dotted line), and 
P-creatinine concentrations in relation to neuropsychiatric symptoms and Cotard’s syndrome in 
patient 2.  
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3.9 PAPER IV 
3.9.1 Study design 
In paper IV the signs and symptoms pattern of AINS were studied in a larger group of 
patients. AINS has earlier been described mainly in case reports including 1-6 patients. 
Data from SWEDIS, our TDM database and published cases were compiled. Signs and 
symptoms were collated along with clinical and laboratory findings. In addition, we 
wanted to evaluate if CNS symptoms in patients with herpes encephalitis could be 
distinguished from AINS. We therefore studied CNS symptoms found in 81 patients 
with herpes encephalitis using information from four different HSE studies and 
compared these with symptoms of AINS [18-21].  
 
3.9.2 Preliminary results 
Data from 275 patients with AINS were retrieved; mean age 61.1 ± 20.5 years; 55 % 
being females. The most frequent neuropsychiatric symptoms were altered level of 
consciousness (147 patients), confusion (146 patients), hallucinations (95 patients), 
involuntary movements (79 patients), and impaired coordination (63 patients). The 
most frequent symptoms, grouped according to preferred terms, are shown in table 2. 
Renal failure was documented in 215 patients (78 %). ACV was given orally to 188 (70 
%) patients and intravenously to 83 (30 %) patients. The main indications were 
varicella zoster infection in 180 (66 %) patients and herpes simplex infection in 49 (18 
%) patients. Almost 60 % of the patients received recommended doses adjusted to renal 
function. 
 
Table 2. The most frequent neuropsychiatric symptoms in AINS patients  
 
AINS symptoms grouped No of patients % 
Altered levels of consciousness 147 54 % 
Confusion 146 53 % 
Hallucinations 95 35 % 
Involuntary movements 79 29 % 
Impaired coordination 63 23 % 
Agitation 50 18 % 
Speech disorder 47 17 % 
Incoherence 33 12 % 
Apathy 32 12 % 
 
We also found that the ratio between serum CMMG and ACV concentrations in AINS 
subjects was 3.31 ± 3.29. The corresponding value for patients without known 
neuropsychiatric adverse reactions in our TDM database was 0.68 ± 4.10 (p<0.001). 
This study confirms that altered level of consciousness, confusion, and hallucinations 
are the most frequent clinical characteristics of AINS. Renal failure is a major risk 
factor.  
 
We found that more than 80 % of HSE patients presented with high fever, altered level 
of consciousness, focal neurological signs, and headache (Table 3). Altered level of 
consciousness was also the most frequent symptom in AINS patients, but to a lesser 
extent (54 %). Other frequent symptoms, such as visual and auditory hallucinations, 
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involuntary movements, impaired coordination, and agitation was present in AINS 
patients, but not in HSE patients. Importantly, the frequency of confusion/disorientation 
was not significantly different from patients with HSE.  
 
 Table 3. The most frequent signs and symptoms in patients with herpes 
encephalitis (HSE) 
 
HSE symptoms grouped % 
Fever 99 %
Altered level of consciousness 95 %
Focal neurological signs 89 %
Headache 77 %
Autonomic-nervous system dysfunction 75 %
Confusion/Disorientation 72 %








3.10 PAPER V 
 
3.10.1 Study design 
Even if our earlier studies supported the primary hypothesis of a correlation between 
CMMG and AINS, it was considered particularly important to obtain detailed 
description of the pharmacokinetics (PK) of CMMG and its relation to renal function. 
Thus, we performed a PK study including patients with various degrees of renal 
function. Paper V describes a single-dose, open-label PK crossover study consisting of 
one i.v. part and one oral. Exposure (AUC), bioavailability, half-life, CL and several 
other PK parameters were estimated. Renal function was estimated using measured 
creatinine clearance, Cockroft-Gaults equation [125], MDRD [120], and CKD-Epi 
[126].  
 
3.10.2 Preliminary results 
Sixteen patients were included in the study: six healthy volunteers with an estimated 
GFR above 70 mL/min, six volunteers with chronic kidney disease (CKD) with a GFR 
between 60 to 20 mL/min, and four patients on HD. The mean CMMG levels in HD 
patients were increased more than 10-fold compared to healthy volunteers (Figure 7). 
Subjects with normal and even patients with impaired renal function had CMMG levels 
close to or below LOQ.  
  
Figure 7. ACV and CMMG concentrations after a single intravenous administration of 100 mg ACV to 
six healthy subjects and 50 mg to six subjects with impaired renal function (CKD) and four HD-patients. 
The ACV metabolite CMMG accumulates in HD patients, while both healthy and CKD subjects show low 
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3.10.3 ACV and CMMG PK and renal function 
ACV and CMMG PK depended heavily on renal function (Figure 8). Bioavailability 
was significantly higher in HD patients than in CKD patients (p= 0.021) despite the 
fact that they had received the same dose. A single HD decreased the ACV and 
CMMG serum concentrations by 56 and 73 %, respectively. We conclude that dose 
regimens aiming to minimize CMMG exposure can be developed based on these data. 
This will allow further examinations of the causality of CMMG in AINS and studies on 
how to avoid it.  
 
Figure 8. The relation between measured creatinine clearance on X-axis and total ACV-CL (open 


















































The hypothesis presented in this thesis is that aciclovir-induced adverse reactions 
emanates from increasing concentrations of the ACV main metabolite CMMG. As 
with all ADRs, the diagnosis of AINS has been a differential diagnosis [127]. It has 
been based on the pattern of neuropsychiatric symptoms [81,91], negative blood and 
CSF tests for viral infection, improvement after discontinuation of ACV, or by HD 
[99,103,117,128,129]. However, the diagnosis has in some cases been confused with 
symptoms from the underlying disease (confounding by indication), resulting in 
increased doses of ACV instead of withdrawal [7,8,130]. This has lead to a demand for 
a test to diagnose AINS.  
 
This thesis suggests that a simple, fast, and reliable diagnostic test for measurement of 
CMMG and ACV in serum, CSF, and urine, may provide valuable information to 
solve the longstanding problem of diagnosing AINS. The conclusion that CMMG is 
either important for the development, or a marker, of AINS is based on ADR case 
reports, pharmacoepidemiology studies, TDM data, and a pharmacokinetic study.  
 
4.1 PAPER I 
In the first paper (Paper I) we found that patients with AINS had significantly higher 
CMMG serum concentrations than did asymptomatic patients. A conventional ROC 
analysis showed that a CMMG serum cut-off value of roughly 11 µmol/L had a higher 
sensitivity and specificity to predict AINS than ACV exposure, ACV concentrations 
and renal function tests. However, a S-creatinine value above 251 µmol/L and ClCr < 17 
mL/min had a sensitivity of 94 % and 88 %, respectively, indicating that impaired renal 
function played an important role in the development of AINS. Despite the fact that 
several patients received doses adapted to renal function, the significantly higher ACV 
exposure in the AINS group, compared to the asymptomatic group, raised the question 
if these patients had divergent bioavailability. Asymptomatic patients had a 
significantly higher GFR compared to AINS patients, 29.6 ± 27.4 mL/min/1.73 m2 and 
19.5 ± 21.1 mL/min/1.73 m2, respectively (p=0.04) (Figure 9).  
 
Figure 9. Renal function calculated by the MDRD formula in patients with AINS and asymptomatic 
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It thus appeared that higher oral ACV doses increased the risk of developing AINS. 
More surprising was the finding that neither the oral VACV, nor the i.v. ACV dose 
differed significantly between the two groups. Again, impaired renal function seemed 
to be an important factor predisposing for the development of AINS. The symptom 
profile of AINS did not differ from published cases, except for a few symptoms such as 
pronounced tiredness, somnolence and restlessness. This discrepancy probably 
reflected a difference in describing symptoms in the patient charts. This problem was 
even more pronounced in paper IV, where we compared symptoms described in our 
Swedish cases and in case reports.  
 
4.1.1.1 Outcome 
Thirty-nine out of the 49 AINS patients recovered. Six patients died in close connection 
to the adverse event, four of them while unconscious and on ACV therapy. The number 
of deaths was unexpectedly high and none of them had signs or symptoms of CNS 
infection. Furthermore, three of the deceased and two of the surviving patients had 
developed cerebral lesions.  
 
4.1.1.2 AINS, hypertension and posterior reversible encephalopathy syndrome 
(PRES) 
Concerning the development of cerebral lesions in AINS patients one can speculate if 
high concentrations of ACV, or its metabolites, might cause hypertension in vulnerable 
subjects. In study IV we found that 32 of 275 patients (12 %) had increased blood 
pressure or malignant hypertension in close relation to the ADR event. We have 
reported a case of an aciclovir-induced MRI-verified posterior leucoencephalopathy, 
developing in a PD-patient with shingles. The patient became agitated, developed 
visual hallucinations and drowsiness, and had a blood pressure of 180/104 mm Hg. 
The highest ACV and CMMG concentrations were 35 µmol/L and 149 µmol/L, 
respectively. MRI showed posterior white matter changes, predominantly in the 
occipital and parietal lobes [131].  
 
Heye et al reported a case of vasculitic, hypoxic-ischemic leucoencephalopathy in a 
67-year-old woman with HD on ACV [132]. In addition, Blohm et al reported a 12-
year-old girl who developed focal secondary generalizing epileptic fits, following a 4 
week prophylactic administration of ACV. Brain MRI demonstrated multiple 
gadolinium-enhancing areas, with impairment of the blood-brain barrier in cortical 
and subcortical regions. Clinical symptoms and neuroimaging pathology resolved 
completely within 9 days of acyclovir withdrawal [97]. 
 
AINS share some of the features of posterior reversible encephalopathy syndrome 
(PRES), i.e. confusion, seizures, and posterior transient changes on neuroimaging 
[131]. It has been suggested that PRES is related to the breakthrough of 
autoregulation in the brain and endothelial dysfunction [133]. It is important to stress 
the fact that increased blood pressure might be caused by the neuropsychiatric 
symptoms, e.g. anxiety and hallucinations, occurring in AINS. However, the 
increased blood pressure seen in AINS patients eventually returned to its previous 
level when the ACV and CMMG concentrations decreased.  
 
 24 
4.2 PAPER II 
To our knowledge Paper II was the first study to demonstrate the presence of CMMG 
in CSF. The result provided further support for the primary hypothesis that CMMG is 
involved in the development of neuropsychiatric side effects in ACV- or VACV-treated 
patients. Another finding was the linear correlation between CMMG serum and CSF 
concentrations.   
 
Recently Smith and colleagues presented a study on PK of ACV and its metabolites 
after the administration of high-dose VACV in subjects with normal and impaired 
renal function [134]. Subjects with normal renal function had a maximum CMMG 
concentration (Cmax) in CSF of 0.095 ± 0.046 µmol/L (range 0.034 – 0.16). CKD 
patients had a higher Cmax: 0.37 ± 0.20 (0.17-0.58) µmol/L. On the whole both 
groups exhibited CMMG concentrations below the LOQ we used in our study (<0.5 
µmol/L). The ACV CSF-to-plasma AUC ratio in healthy subjects and CKD patients 
were 0.27 and 0.28, respectively, while the corresponding values for CMMG CSF-to-
plasma AUC ratio were 0.025 and 0.026, respectively. CSF concentrations of ACV, 
as well as CMMG and the second ACV metabolite 8-OH-ACV, were stable during 
the study. Similar results were reported by Lycke and colleagues, suggesting a slow 
transport in and out of CSF [115]. This slow transport has also been discussed in a 
review article by Löscher and Potschka [135].  
 
Data from 13 AINS patients included in study IV showed a mean ACV CSF-serum 
ratio of 0.20 ± 0.17. In study II the ACV CSF-to-serum ratio in asymptomatic patients 
as well as in AINS patients were median 0.3 (range 0.2 to 1.46) and 0.46 (range 0.23 
to 2.50), respectively. It can also be noted that describing the distribution of ACV and 
CMMG across the BBB as a constant ratio is apparently inaccurate, as the 
fluctuations in serum is much larger than the fluctuation in the CSF. This may explain 
much of the confusion in the published literature regarding the BBB distribution of 
ACV.  
 
4.2.1.1 Drug transporters in the brain 
The results in paper II cannot be discussed without a brief description of drug 
transporters in the brain. I will focus on the blood-brain barrier (BBB) as a protection 
barrier, preventing toxic substances to enter the brain. BBB forms a diffusion barrier 
with tight junctions between the endothelial cells. Lipophilic compounds with low 
molecular weight may enter the brain by passive diffusion, while other lipophilic 
compounds cannot, due to transporter protein activity. The barrier consists not only of 
tight junctions preventing substances to enter, but also of proteins that function as 
transporters. There are several transporters present in the BBB, but also in the blood- 
CSF barrier. They regulate the in- and out flux of substances from the blood to the 
brain tissue.  
 
Among these transporters P-glycoprotein (Pgp), multidrug resistance proteins (MRPs) 
and anion and cation transporting polypeptides (OAT and OCT) are the most important 
and most studied. Pgp is mainly expressed at the apical side of the brain capillary 
endothelial cells, pumping out Pgp substrates back to the blood. Inhibition of Pgp may 
lead to increased concentrations of a toxic substance or drug in the brain [135].  
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It has been suggested that ACV is an inhibitor of OAT3. It was shown in an in vitro-
study that the transport of indoxyl sulphate, a uremic toxin found in renal failure 
patients and a marker substance for neurotransporter metabolites, was inhibited by 
ACV. This indicates that ACV may increase the accumulation of these substances in 
the brain [136]. If this is applicable also to CMMG accumulation needs to be 
elucidated.    
 
4.2.1.2 Renal function  
Ten of the 12 asymptomatic patients in paper II have earlier been described concerning 
ACV concentrations, but without measurement of CMMG. Their estimated renal 
function was 90 ± 21 mL/min. Their mean (± SD) ACV and CMMG serum 
concentrations are shown in Figure 10.  
Figure 10. The figure shows ACV and CMMG concentrations in patients with normal renal function on 
VACV. The CMMG serum concentrations are low and in line with previous publications [38]. The 
parallel disappearance of ACV and CMMG suggests that the kinetics of CMMG in healthy subjects with 
normal renal function is formation and not elimination dependent. Observe the log scale on the Y-axis. 
ACV = straight line, CMMG= dotted line. 
 
4.2.1.3 Conclusions from paper II 
The results from paper II and the discussion in the paragraphs above can be 
summarized as follow:  
 
• CMMG could be found in CSF only in patients with AINS. 
• All but one patient with AINS had impaired renal function.  
• CMMG serum levels were low in asymptomatic subjects, while the mean 
values were 90 times higher in AINS patients. 
• Measurement of CMMG in CSF might be the most accurate method to 
diagnose AINS.  
• Inhibition of transporter proteins in the brain tissue may be involved in the 






























4.3 PAPER III 
Paper III describes two patients with Cotard’s syndrome. After the initiation of VACV, 
in one case followed by i.v. ACV, both patients experienced a strong belief that they 
were dead. We could show a close relation between high CMMG concentrations in 
serum and the experienced symptoms. The implication that an ADR may cause the 
syndrome has not been shown before.  
 
4.3.1 The syndrome 
Cotard’s syndrome was first described by the French neurologist Jules Cotard in 1880. 
He presented a female patient with “délire des negations” [137,138]. The syndrome 
“comprises any one of a series of delusions ranging from the fixed and unshakable 
belief that one has lost organs, blood, or body parts to believing that one has lost one’s 
soul or is dead” [139]. Cotard’s can persist for a long period, even for years. However, 
in our female patient it disappeared already after a single dialysis, suggesting that there 
is a concentration dependent effect on the brain from ACV or CMMG. Cotard’s 
syndrome has been observed in schizophrenia, melancholic depression and other 
psychiatric diseases, but also in other somatic conditions such as Parkinson’s disease 
and in patients with cerebral lesions. It is a rare condition and less than one case per 
year has been published since 1880. Interestingly, we found in study IV that depression 
and suicidal ideation were present in 5 % of the 275 investigated patients. Only recently 
Asahi and colleagues reported a 73-year-old male HD patient who developed 
confusion, hallucinations and a fear of “going to die” after VACV was initiated in a 
dose of 3000 mg/day [140]. Apparently, ACV treatment in ESRD patients may induce 
symptoms of depression, which disappear within a few hours on dialysis.  
 
4.3.2 Might cerebral lesions be the cause? 
Cotard’s syndrome has been linked to damage of the non-dominant temporo-parietal 
cerebral cortex. Hypoperfusion in the temporal, parietal and frontal lobes have also 
been reported, which almost disappeared in one case after successful ECT (electro-
convulsive therapy) treatment [141].  
 
4.4 PAPER IV 
Paper IV describes aciclovir-induced adverse symptoms in 275 patients and also 
presents a comparison between AINS and symptoms reported for HSE. One of the 
databases, SWEDIS, is not as comprehensive in its structure as published case reports. 
The most important symptoms were however noted in these ADR reports, and 
information could also be extracted from the text in the report.  
 
Two important findings in the study were that the majority of AINS patients were 
treated with oral ACV or VACV and that shingles was the most common indication. 
Women received the same doses as men. The annual incidence to develop shingles 
increases with age, as shown in paragraph 1.4.1. Elderly women with age-related 
kidney function decline may be more vulnerable to develop AINS. Renal function in 
elderly patients should therefore always be checked before and during treatment with 
ACV or VACV. We have recently shown that many elderly patients developing ARDs 
had low renal function [142].   
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Our study also showed that HSE patients usually presented with distinct symptoms 
such as high fever, altered level of consciousness, focal neurological signs, and 
headache. Other symptoms more frequently observed in HSE patients were seizures, 
vomiting and hemiparesis. However, as many as 50 % of HSE and AINS patients had 
confusion and altered level of consciousness, making it difficult to distinguish AINS 
from HSE in these cases.  
 
4.4.1 Other symptoms 
Forty-seven patients (17 %) developed gastrointestinal symptoms and 44 patients 
developed hypoxia, or lung symptoms, generally requiring mechanical ventilation. The 
mechanism behind this is still unknown, but similar cases have been reported [143]. 
  
4.4.2 Investigations 
The results from investigations performed in AINS patients, such as CT, MRI, and 
lumbar puncture, are in most cases normal and help to facilitate the diagnostic 
procedure. EEG in HSE may show lateralisation and periodic spike and slow-wave 
activity emanating from the infected hemisphere. However, EEG has a sensitivity of 
approximately 84 %, but specificity is not higher than 33 % [12]. EEG in AINS 
patients is in general described as metabolic encephalopathy with diffuse slowing [81]. 
 
4.4.3 AINS and delirium 
We found the grading of neuropsychiatric symptoms to be difficult. Many aciclovir-
induced adverse reactions corresponded to symptoms present in delirium, such as 
confusion, psychosis, disorientation, and frightening visual hallucinations. Several 
formal instruments have been developed to diagnose delirium. These are aiming to help 
the clinicians to support the diagnosis of a condition which is complicated to assess. In 
paper IV we used four different assessment scales, but none of them could entirely 
cover all the different symptoms present in AINS.  
 
4.4.4 Conclusion paper IV 
We conclude that it is difficult to distinguish between CNS symptoms in patients with 
HSE and patients with AINS. This view was also put forward as it was found that the 
clinical findings of HSE are non-specific, and that the symptom profile itself cannot be 
the only tool to support the diagnosis [12]. The AINS profile presented in paper IV is a 
valuable tool in the diagnosis of AINS, but may alone be insufficient when 
distinguishing from herpes or varicella encephalitis. Therefore TDM of ACV, and in 
particular, its main metabolite CMMG, is recommended. 
 
4.5 PAPER V 
In paper V the PK of ACV and CMMG were studied in patients with various degrees of 
renal function, aiming to provide PK parameter estimates for developing ACV dose 
recommendations. Our goal was to find an ACV concentration above the inhibitory 
dose (ID50) for HSV and VZV, but without increased concentrations of CMMG and 
risk for AINS. Low doses were used to avoid the development of AINS in the 
participants. This resulted in low CMMG concentrations in subjects with normal renal 
function and patients with moderately impaired renal function. However, ACV 




For some individuals the parameter estimates are uncertain. Nevertheless, the relation 
between renal function and the clearance of both ACV and CMMG could in some cases 
be established and was linear. The results obtained can be utilized to develop dose 
regimens aimed to maximize the ACV exposure compared to CMMG exposure. 
 
   29 
4.6 OTHER ASPECTS OF AINS 
 
4.6.1 How to explain the lack of relation between high ACV 
concentrations and AINS? 
The RIA methods had high sensitivity and specificity, and could separate ACV from 
CMMG. As mentioned earlier, there had only been one instance where CMMG had 
been found in the serum of a patient [64]. The HPLC assay developed by Svensson et 
al did also have high sensitivity and specificity, and furthermore, it could also separate 
CMMG from ACV. This method was unique and other laboratories did not have this 
facility.  
 
A French AINS case can illustrate the problem with a HPLC method which cannot 
separate ACV from CMMG. A 64-year-old woman on HD developed altered level of 
consciousness four days after the initiation of i.v. ACV, 5mg/kg qid. ACV 
concentrations were initially analyzed by a HPLC method. The first sample was 
collected two days after discontinuation of ACV, the remaining two after two separate 
HD sessions. The analysis of ACV showed 80, 98, and 124 µmol/L, respectively. 
Surprisingly the ACV concentrations increased despite discontinuation of therapy and 
HD. When the same samples were analyzed by the more sensitive RIA method, they 
showed 25, 2.8 and 0.53 µmol/L, respectively [112], similar to the decrease reported 
earlier after HD [117]. A reasonable hypothesis is that the HPLC method did not 
separate between ACV and CMMG, and that the increasing ACV levels represented 
CMMG concentrations.  
 
4.6.2 Treatment of AINS 
ACV should be discontinued in a patient developing AINS and dehydrated patients 
should receive fluid. Forced diuresis has been tried in patients with AINS and ARF, but 
the rational for this measure is unclear and has not been studied in AINS patients. Cases 
with breathing difficulties, confusion, stupor, and coma have been reported to benefit 
from a 3-4 hrs HD, which may be repeated if the patient does not recover after the first 
HD session [103]. 
 
4.6.2.1  Low dose ACV in ESRD patients. 
Doses lower than recommended in the PDR has been tried in patients on HD to avoid 
AINS. Almond et al performed a pharmacokinetic study in seven HD-patients. 
Computer modelling showed that sufficient ACV concentrations could be achieved 
with a loading dose of 400 mg, and a maintenance dose of 200 mg twice daily. The 
model suggests that a further loading dose of 400 mg should be administered after each 
dialysis session [144]. We tried the dose recommendations presented in the study and 
measured ACV and CMMG concentrations in two patients, one on HD and the other 
on PD. Figure 11a shows that ACV concentrations were within the range suggested to 
be effective against HSV and VZV. CMMG concentrations were low and not in the 
range seen in patients with AINS. Both ACV and CMMG concentrations were 
increasing in the PD patient, suggesting that PD patients may pose an increased risk for 








Figure 11. a) ACV and CMMG concentrations in a hemodialysis patient given oral ACV in a dose of 200 
mg x 2. b) ACV and CMMG concentrations in a patient on peritoneal dialysis administered oral ACV in 
a dose of 200 mg x 2. ACV and CMMG show increasing concentrations, beginning four days after the 
initiation of the therap. This may increase the risk for developing AINS. ACV clearance during PD is 
approximately 3 mL/min [145]. Hence, regular PD cannot be used to decrease increased concentrations 
of ACV and CMMG.  
  
4.6.3 Are there any other possible causes to the development of AINS? 
 
It is evident that there may be several other factors that may contribute to the 
development of AINS. We have focused on the relation between AINS and CMMG. 
We cannot rule out that the second ACV metabolite 8-OH-ACV may be responsible for 
the development of AINS. It is also possible that the transport of other substances in the 
brain causing AINS might be inhibited by ACV or any of its metabolites. Direct studies 
of the effects of CMMG per se are obviously needed to further illuminate the 
mechanisms involved. 
 
Importantly, the present data does not provide direct evidence that CMMG is the cause 
of AINS. There are some publications arguing in favour of the CMMG hypothesis 
[114,131,146-148], but there are also alternative hypotheses. In one study it was found 
that there were increased concentrations of CMMG in hemodialysis patients who did 
not exhibit neuropsychiatric reactions [134]. There is no obvious explanation to this 
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5 FUTURE PERSPECTIVES AND GENERAL 
CONCLUSIONS 
 
5.1 FUTURE PERSPECTIVES 
A large number of aspects of AINS suggest future studies. Some of these are included 
below: 
 
• To measure neurotransmitter and/or its metabolites in AINS patients.  
 
• To study the impact of drug transporters in the BBB and blood-CSF barrier 
and the development of AINS. 
 
• To study the metabolism of ACV in different ethnic groups to better predict 
the development of AINS. 
 
• To develop a new assessment scale for AINS events. 
 
• To study possible toxicity of CMMG. 
 
• To study the presence and impact of the ACV aldehyde. 
 




From the results obtained in this thesis it is concluded that: 
 
• The ACV main metabolite 9-carboxymethoxymethylguanine (CMMG) is 
consistently increased in patients with AINS. 
 
• CMMG has a higher sensitivity and specificity as a predictor of AINS than 
ACV concentrations and estimates of renal function.  
 
• CMMG, as well as ACV, enters the brain and can be detected in CSF. 
 
• Impaired renal function appears to be the main risk factor for development of 
AINS.  
 
• AINS may present as a delusion of being dead.  
 
• AINS are most common in patients with herpes zoster and after oral treatment. 
 
• The most frequent symptoms seen in AINS patients are altered level of 
consciousness, confusion, hallucinations and involuntary movements, while 
patients with HSE have significantly higher frequency of high fever, altered 
level of consciousness, focal neurological signs, and headache. 
 
• AINS may be difficult to distinguish from herpes encephalitis, and probably 
also other viral CNS infections, if the assessment is based solely on the 
symptom profiles. 
 
• Dose regimens aimed to minimize CMMG exposure may be developed based 
on the pharmacokinetic results. 
 
• The results of this thesis support the hypothesis that CMMG is a useful 
predictor of AINS and it may be mechanistically involved. Determination of 
CMMG concentrations may be a useful tool to distinguish between AINS and 
symptoms from viral CNS infections.  
 
Finally, this thesis is an example of how serendipity (the ability to make a discovery by 
a lucky chance) and curiosity can create a new field of research. 
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